We serve Chemical Name:2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile CAS:643015-36-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile
CAS.NO:643015-36-5
Synonyms:2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile
Molecular Formula:C8H5F3N2
Molecular Weight:186.13400
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:36.68000
Exact Mass:186.04000
LogP:2.28048
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile Use and application,2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile technical grade,usp/ep/jp grade.
Related News: Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. 2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile supplier It is delivered to hospitals and pharmacies until it reaches the patient. 2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile vendor Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry. 2-methyl-4-(trifluoromethyl)pyridine-3-carbonitrile factory Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).
